**COVID STEROID trial**

**Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia**

*Objective: To assess the effects of low-dose intravenous hydrocortisone on the number of days alive without life-support in adult patients with COVID-19 and severe hypoxia.*

# Inclusion criteria

* Aged 18 years or above **AND**
* Confirmed SARS-CoV-2 (COVID-19) requiring hospitalisation **AND**
* One of the following:
	+ Invasive mechanical ventilation **OR**
	+ Non-invasive ventilation or continuous use of CPAP for hypoxia **OR**
	+ Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system

**If eligible contact tel. \_\_\_\_\_\_\_\_**

# Intervention

Active medication: hydrocortisone, powder and solvent solution for intravenous injection, 100 mg

* Continues infusion of hydrocortisone 200 mg (4 ml) mixed with 100 ml isotonic NaCl with infusion rate 4.3 ml/hour **OR**
* Bolus injection of 50 mg hydrocortisone mixed in 9 ml solution of isotonic NaCl every 6 hours (bolus volume 10 ml)

# Comparator

Placebo drug: Isotonic saline, solution for intravenous injection, 9mg/ml

* Continues infusion of 104 ml isotonic NaCl with infusion rate 4.3 ml/hour **OR**
* Bolus injection of 10 ml isotonic NaCl every 6 hours

# Intervention period

Hydrocortisone or placebo for 7 days **OR** until discharge from participating site **OR** until death (whichever comes first)